Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Current Deferred Revenue (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Current Deferred Revenue for 5 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Deferred Revenue fell 31.41% year-over-year to $1.4 million, compared with a TTM value of $1.4 million through Sep 2025, down 31.41%, and an annual FY2024 reading of $1.7 million, changed N/A over the prior year.
  • Current Deferred Revenue was $1.4 million for Q3 2025 at Barinthus Biotherapeutics, down from $1.5 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $2.0 million in Q3 2024 and bottomed at $162000.0 in Q1 2022.
  • Average Current Deferred Revenue over 4 years is $962166.7, with a median of $1.1 million recorded in 2024.
  • The sharpest move saw Current Deferred Revenue crashed 53.18% in 2022, then skyrocketed 81.76% in 2025.
  • Year by year, Current Deferred Revenue stood at $182000.0 in 2021, then fell by 10.99% to $162000.0 in 2022, then skyrocketed by 972.84% to $1.7 million in 2024, then decreased by 19.33% to $1.4 million in 2025.
  • Business Quant data shows Current Deferred Revenue for BRNS at $1.4 million in Q3 2025, $1.5 million in Q2 2025, and $1.5 million in Q1 2025.